These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38699357)

  • 1. Default mode network tau predicts future clinical decline in atypical early Alzheimer's disease.
    Katsumi Y; Howe IA; Eckbo R; Wong B; Quimby M; Hochberg D; McGinnis SM; Putcha D; Wolk DA; Touroutoglou A; Dickerson BC
    medRxiv; 2024 Apr; ():. PubMed ID: 38699357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal default mode sub-networks in the language and visual variants of Alzheimer's disease.
    Sintini I; Corriveau-Lecavalier N; Jones DT; Machulda MM; Gunter JL; Schwarz CG; Botha H; Carlos AF; Kamykowski MG; Singh NA; Petersen RC; Jack CR; Lowe VJ; Graff-Radford J; Josephs KA; Whitwell JL
    Brain Commun; 2024; 6(2):fcae005. PubMed ID: 38444909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau and the fractionated default mode network in atypical Alzheimer's disease.
    Putcha D; Eckbo R; Katsumi Y; Dickerson BC; Touroutoglou A; Collins JA
    Brain Commun; 2022; 4(2):fcac055. PubMed ID: 35356035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes.
    Sintini I; Graff-Radford J; Senjem ML; Schwarz CG; Machulda MM; Martin PR; Jones DT; Boeve BF; Knopman DS; Kantarci K; Petersen RC; Jack CR; Lowe VJ; Josephs KA; Whitwell JL
    Brain; 2020 Jul; 143(7):2281-2294. PubMed ID: 32572464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline [
    Teng E; Manser PT; Sanabria Bohorquez S; Wildsmith KR; Pickthorn K; Baker SL; Ward M; Kerchner GA; Weimer RM
    Alzheimers Res Ther; 2021 Dec; 13(1):196. PubMed ID: 34852837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease.
    Lehmann M; Ghosh PM; Madison C; Laforce R; Corbetta-Rastelli C; Weiner MW; Greicius MD; Seeley WW; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2013 Mar; 136(Pt 3):844-58. PubMed ID: 23358601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
    JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resting-state functional connectivity and amyloid burden influence longitudinal cortical thinning in the default mode network in preclinical Alzheimer's disease.
    Hampton OL; Buckley RF; Manning LK; Scott MR; Properzi MJ; Peña-Gómez C; Jacobs HIL; Chhatwal JP; Johnson KA; Sperling RA; Schultz AP
    Neuroimage Clin; 2020; 28():102407. PubMed ID: 32942175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of tau deposition using
    Bullich S; Mueller A; De Santi S; Koglin N; Krause S; Kaplow J; Kanekiyo M; Roé-Vellvé N; Perrotin A; Jovalekic A; Scott D; Gee M; Stephens A; Irizarry M
    Alzheimers Res Ther; 2022 Jul; 14(1):105. PubMed ID: 35897078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
    Malpetti M; Kievit RA; Passamonti L; Jones PS; Tsvetanov KA; Rittman T; Mak E; Nicastro N; Bevan-Jones WR; Su L; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2020 May; 143(5):1588-1602. PubMed ID: 32380523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease.
    Tanner JA; Iaccarino L; Edwards L; Asken BM; Gorno-Tempini ML; Kramer JH; Pham J; Perry DC; Possin K; Malpetti M; Mellinger T; Miller BL; Miller Z; Mundada NS; Rosen HJ; Soleimani-Meigooni DN; Strom A; La Joie R; Rabinovici GD
    Brain; 2022 Dec; 145(12):4489-4505. PubMed ID: 35762829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease.
    Phillips JS; Das SR; McMillan CT; Irwin DJ; Roll EE; Da Re F; Nasrallah IM; Wolk DA; Grossman M
    Hum Brain Mapp; 2018 Feb; 39(2):691-708. PubMed ID: 29105977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease.
    Ossenkoppele R; Cohn-Sheehy BI; La Joie R; Vogel JW; Möller C; Lehmann M; van Berckel BN; Seeley WW; Pijnenburg YA; Gorno-Tempini ML; Kramer JH; Barkhof F; Rosen HJ; van der Flier WM; Jagust WJ; Miller BL; Scheltens P; Rabinovici GD
    Hum Brain Mapp; 2015 Nov; 36(11):4421-37. PubMed ID: 26260856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals.
    d'Oleire Uquillas F; Jacobs HIL; Hanseeuw B; Marshall GA; Properzi M; Schultz AP; LaPoint MR; Johnson KA; Sperling RA; Vannini P
    Neuroimage Clin; 2018; 17():388-396. PubMed ID: 29159051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals.
    Ingala S; Tomassen J; Collij LE; Prent N; van 't Ent D; Ten Kate M; Konijnenberg E; Yaqub M; Scheltens P; de Geus EJC; Teunissen CE; Tijms B; Wink AM; Barkhof F; van Berckel BNM; Visser PJ; den Braber A
    Brain Commun; 2021; 3(4):fcab201. PubMed ID: 34617016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of cortical microstructure with amyloid-β and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults.
    Rodriguez-Vieitez E; Montal V; Sepulcre J; Lois C; Hanseeuw B; Vilaplana E; Schultz AP; Properzi MJ; Scott MR; Amariglio R; Papp KV; Marshall GA; Fortea J; Johnson KA; Sperling RA; Vannini P
    Mol Psychiatry; 2021 Dec; 26(12):7813-7822. PubMed ID: 34588623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates of longitudinal change in
    Phillips JS; Nitchie FJ; Da Re F; Olm CA; Cook PA; McMillan CT; Irwin DJ; Gee JC; Dubroff JG; Grossman M; Nasrallah IM;
    Alzheimers Dement; 2022 Jun; 18(6):1235-1247. PubMed ID: 34515411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease.
    Zimmer JA; Shcherbinin S; Devous MD; Bragg SM; Selzler KJ; Wessels AM; Shering C; Mullen J; Landry J; Andersen SW; Downing AM; Fleisher AS; Svaldi DO; Sims JR
    Alzheimers Dement (N Y); 2021; 7(1):e12123. PubMed ID: 33614894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.